BMO reaffirms Eli Lilly (LLY) as a dominant player in the obesity drug market, citing robust performance from Mounjaro and Zepbound. The move boosts investor confidence in LLY’s long-term growth trajectory within the high-potential metabolic health sector.
- Mounjaro generated over $2.8 billion in obesity-related revenue in the latest quarter
- Zepbound contributed approximately $1.6 billion in the same period
- LLY leads in dual GIP/GLP-1 receptor agonist therapy development
- Global obesity drug market expected to surpass $100 billion by 2030
- BMO maintains positive investment rating on LLY amid strong clinical and commercial execution
- Competitive positioning strengthened against Novo Nordisk (NVO) and Pfizer (PFE)
BMO has reinforced its positive outlook on Eli Lilly and Company (LLY), maintaining its position as a leading force in the global obesity therapeutics market. This endorsement follows sustained commercial success of LLY’s GLP-1-based therapies, particularly Mounjaro (tirzepatide) and Zepbound (also tirzepatide), which have demonstrated significant weight reduction outcomes in clinical trials and real-world use. The firm highlighted that LLY’s obesity indications for Mounjaro achieved over $2.8 billion in annualized sales in the most recent quarter, reflecting rapid adoption across U.S. and international markets. Additionally, Zepbound, approved for chronic weight management, contributed approximately $1.6 billion in revenue during the same period, signaling strong demand beyond diabetes treatment. These figures underscore LLY’s expanding footprint in a rapidly growing segment projected to exceed $100 billion globally by 2030. Market analysts note that LLY’s lead in next-generation dual agonists—targeting both GIP and GLP-1 receptors—positions it ahead of competitors such as Novo Nordisk (NVO) and Pfizer (PFE). BMO emphasized that LLY’s manufacturing scale, clinical pipeline depth, and favorable reimbursement trends in key regions like the United States and Europe are likely to sustain its leadership in the coming years. The reaffirmation comes at a time when investor interest in biotech and metabolic disease solutions is intensifying, especially following Q4 earnings reports across major pharma firms. Investors and stakeholders in the pharmaceutical and healthcare sectors now view LLY as a bellwether for innovation in chronic disease management. The stock has seen upward momentum since the announcement, with analysts adjusting forward guidance upward for FY2026 and beyond.